Concentration and activity of the soluble form of the interleukin-7 receptor a in type 1 diabetes identifies an interplay between hyperglycemia and immune function

Paolo Monti, Cristina Brigatti, Miriam Krasmann, Anette G. Ziegler, Ezio Bonifacio

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Soluble interleukin-7 (IL-7) receptor a (sCD127) is implicated in the pathogenesis of autoimmune diseases. We show that serum sCD127 concentrations are increased at the onset of type 1 diabetes (T1D; n = 390) as compared with concentrations in agematched islet autoantibody-negative first-degree relatives of patients (n = 392; P = 0.00001). sCD127 concentration in patients was influenced by islet autoantibody status (P = 0.003) and genotype of the rs6897932 single nucleotide polymorphism within the IL-7RA gene (P = 0.006). Release of sCD127 in vitro was strongly upregulated by activation of T lymphocytes and affected by exposure to cytokines. sCD127 bound IL-7 and was antagonistic to IL-7 signaling and IL-7-mediated T-cell proliferation, suggesting a regulatory feedback mechanism on T-cell expansion. Remarkably, high glucose led to a glycated form of sCD127 that was ineffective as an IL-7 antagonist. The finding of glycated sCD127 in the circulation of patients at onset of T1D suggested that physiological regulation of IL-7-mediated T-cell survival and expansion by sCD127 may be compromised in T1D. The findings indicate that genetic, immunologic, and metabolic factors contribute to a dysregulation of the IL-7/IL-7 receptor pathway in T1D and identify a novel hyperglycemia-mediated interference of immune regulatory networks.

Original languageEnglish
Pages (from-to)2500-2508
Number of pages9
JournalDiabetes
Volume62
Issue number7
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Interleukin-7 Receptors
Interleukin-7
Type 1 Diabetes Mellitus
Hyperglycemia
T-Lymphocytes
Autoantibodies
Immunologic Factors
Autoimmune Diseases
Single Nucleotide Polymorphism
Cell Survival
Genotype
Cell Proliferation
Cytokines
Glucose
Serum

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Concentration and activity of the soluble form of the interleukin-7 receptor a in type 1 diabetes identifies an interplay between hyperglycemia and immune function. / Monti, Paolo; Brigatti, Cristina; Krasmann, Miriam; Ziegler, Anette G.; Bonifacio, Ezio.

In: Diabetes, Vol. 62, No. 7, 07.2013, p. 2500-2508.

Research output: Contribution to journalArticle

Monti, Paolo ; Brigatti, Cristina ; Krasmann, Miriam ; Ziegler, Anette G. ; Bonifacio, Ezio. / Concentration and activity of the soluble form of the interleukin-7 receptor a in type 1 diabetes identifies an interplay between hyperglycemia and immune function. In: Diabetes. 2013 ; Vol. 62, No. 7. pp. 2500-2508.
@article{c5a6f0acbe6b40b281ce36ccd4e0d931,
title = "Concentration and activity of the soluble form of the interleukin-7 receptor a in type 1 diabetes identifies an interplay between hyperglycemia and immune function",
abstract = "Soluble interleukin-7 (IL-7) receptor a (sCD127) is implicated in the pathogenesis of autoimmune diseases. We show that serum sCD127 concentrations are increased at the onset of type 1 diabetes (T1D; n = 390) as compared with concentrations in agematched islet autoantibody-negative first-degree relatives of patients (n = 392; P = 0.00001). sCD127 concentration in patients was influenced by islet autoantibody status (P = 0.003) and genotype of the rs6897932 single nucleotide polymorphism within the IL-7RA gene (P = 0.006). Release of sCD127 in vitro was strongly upregulated by activation of T lymphocytes and affected by exposure to cytokines. sCD127 bound IL-7 and was antagonistic to IL-7 signaling and IL-7-mediated T-cell proliferation, suggesting a regulatory feedback mechanism on T-cell expansion. Remarkably, high glucose led to a glycated form of sCD127 that was ineffective as an IL-7 antagonist. The finding of glycated sCD127 in the circulation of patients at onset of T1D suggested that physiological regulation of IL-7-mediated T-cell survival and expansion by sCD127 may be compromised in T1D. The findings indicate that genetic, immunologic, and metabolic factors contribute to a dysregulation of the IL-7/IL-7 receptor pathway in T1D and identify a novel hyperglycemia-mediated interference of immune regulatory networks.",
author = "Paolo Monti and Cristina Brigatti and Miriam Krasmann and Ziegler, {Anette G.} and Ezio Bonifacio",
year = "2013",
month = "7",
doi = "10.2337/db12-1726",
language = "English",
volume = "62",
pages = "2500--2508",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "7",

}

TY - JOUR

T1 - Concentration and activity of the soluble form of the interleukin-7 receptor a in type 1 diabetes identifies an interplay between hyperglycemia and immune function

AU - Monti, Paolo

AU - Brigatti, Cristina

AU - Krasmann, Miriam

AU - Ziegler, Anette G.

AU - Bonifacio, Ezio

PY - 2013/7

Y1 - 2013/7

N2 - Soluble interleukin-7 (IL-7) receptor a (sCD127) is implicated in the pathogenesis of autoimmune diseases. We show that serum sCD127 concentrations are increased at the onset of type 1 diabetes (T1D; n = 390) as compared with concentrations in agematched islet autoantibody-negative first-degree relatives of patients (n = 392; P = 0.00001). sCD127 concentration in patients was influenced by islet autoantibody status (P = 0.003) and genotype of the rs6897932 single nucleotide polymorphism within the IL-7RA gene (P = 0.006). Release of sCD127 in vitro was strongly upregulated by activation of T lymphocytes and affected by exposure to cytokines. sCD127 bound IL-7 and was antagonistic to IL-7 signaling and IL-7-mediated T-cell proliferation, suggesting a regulatory feedback mechanism on T-cell expansion. Remarkably, high glucose led to a glycated form of sCD127 that was ineffective as an IL-7 antagonist. The finding of glycated sCD127 in the circulation of patients at onset of T1D suggested that physiological regulation of IL-7-mediated T-cell survival and expansion by sCD127 may be compromised in T1D. The findings indicate that genetic, immunologic, and metabolic factors contribute to a dysregulation of the IL-7/IL-7 receptor pathway in T1D and identify a novel hyperglycemia-mediated interference of immune regulatory networks.

AB - Soluble interleukin-7 (IL-7) receptor a (sCD127) is implicated in the pathogenesis of autoimmune diseases. We show that serum sCD127 concentrations are increased at the onset of type 1 diabetes (T1D; n = 390) as compared with concentrations in agematched islet autoantibody-negative first-degree relatives of patients (n = 392; P = 0.00001). sCD127 concentration in patients was influenced by islet autoantibody status (P = 0.003) and genotype of the rs6897932 single nucleotide polymorphism within the IL-7RA gene (P = 0.006). Release of sCD127 in vitro was strongly upregulated by activation of T lymphocytes and affected by exposure to cytokines. sCD127 bound IL-7 and was antagonistic to IL-7 signaling and IL-7-mediated T-cell proliferation, suggesting a regulatory feedback mechanism on T-cell expansion. Remarkably, high glucose led to a glycated form of sCD127 that was ineffective as an IL-7 antagonist. The finding of glycated sCD127 in the circulation of patients at onset of T1D suggested that physiological regulation of IL-7-mediated T-cell survival and expansion by sCD127 may be compromised in T1D. The findings indicate that genetic, immunologic, and metabolic factors contribute to a dysregulation of the IL-7/IL-7 receptor pathway in T1D and identify a novel hyperglycemia-mediated interference of immune regulatory networks.

UR - http://www.scopus.com/inward/record.url?scp=84881483958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881483958&partnerID=8YFLogxK

U2 - 10.2337/db12-1726

DO - 10.2337/db12-1726

M3 - Article

C2 - 23454692

AN - SCOPUS:84881483958

VL - 62

SP - 2500

EP - 2508

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 7

ER -